Clinical trials: Crohn Disease (CD), open to volunteers
- Condition Crohn Disease (CD)
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Crohn Disease, Fibrostenotic Crohn's Disease
Artificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes
The goal of this retrospective observational study is to learn whether artificial intelligence-based digital pathology can measure intestinal fibrosis and help identify patients with Crohn's disease who may be at greater risk of…
- Conditions
- Crohn Disease, Fibrostenotic Crohn's Disease, CD - Crohn's Disease
- Trial name
- AIFOR-CD (NCT07795476)
- Testing
- Ph-FCS(Muc) fibrosis severity Digital Pathology biomarker
- Where
- 2 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PharmaNest, Inc
Crohn Disease (CD)
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow…
- Trial name
- NCT07625293
- Testing
- DB-3Q
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Direct Biologics, LLC
Crohn Disease (CD)
R-3750 in Patients With Crohn's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, clinical activity, and pharmacodynamic effects of R-3750 in adults with active Crohn's disease.
- Trial name
- NCT07791888
- Testing
- R-3750
- Volunteers
- 40 people
- Sponsor
- Rise Therapeutics LLC
Crohn Disease (CD)
HB-adMSCs for the Treatment of Crohn's Disease
Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post…
- Trial name
- NCT07077746
- Testing
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Hope Biosciences Research Foundation
Ulcerative Colitis (UC), Ulcerative Colitis (Disorder)
A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult
A Phase 1, 2-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of BDHK-2009 (Part 1) and multiple oral doses (Part 2) of BDHK-200 in…
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis (Disorder), Ulcerative Colitis Acute, IBD (Inflammatory Bowel Disease)
- Trial name
- NCT07632573
- Testing
- BDHK-2009 Tablets
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Benethera (Shaoxing) Biotechnology Co., Ltd.
Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab.
- Trial name
- NCT04779320
- Testing
- Vedolizumab IV
- Where
- 96 sites in United States, Australia and 16 more
- Volunteers
- 120 people
- Sponsor
- Takeda
Crohn's Disease (CD)
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
The aim of the study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of study drug (BCD-261) in comparison with placebo and to characterize the dose-response relationship in patients…
- Trial name
- COMANDOR (NCT07078994)
- Testing
- anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high dose
- Where
- 20 sites in Russia
- Volunteers
- 204 people
- Sponsor
- Biocad
Crohn Disease (CD)
Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar
In a population of adult patients followed for Crohn's disease, who had previously agreed to replace Stelara® with a biosimilar of ustekinumab (Uzpruvo®) and were followed over a period of 12 months under usual medical practice…
- Trial name
- NCT07077681
- Where
- 11 sites in France
- Volunteers
- 246 people
- Sponsor
- EG Labo
Crohn Disease (CD), Crohns Disease
Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC).
- Conditions
- Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
- Trial name
- NCT07059130
- Testing
- Mirikizumab
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Rubix LS
Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease
This clinical trial is testing a new treatment called L2-01 in patients with Crohn's Disease, a condition that causes ongoing inflammation of the digestive tract.
- Trial name
- NCT07010926
- Testing
- L2-01 adipose-derived mesenchymal stem cells (MSC)
- Volunteers
- 120 people
- Sponsor
- EL3 Bio, LLC.